A third vaccine dose substantially improves humoral and cellular SARS-CoV-2 immunity in renal transplant recipients with primary humoral nonresponse
- 9 September 2021
- journal article
- letter
- Published by Elsevier BV in Kidney International
- Vol. 100 (5), 1135-1136
- https://doi.org/10.1016/j.kint.2021.09.001
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case SeriesAnnals of Internal Medicine, 2021
- Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant RecipientsThe New England Journal of Medicine, 2021
- Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipientsJCI Insight, 2021
- Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patientsAmerican Journal of Transplantation, 2021
- Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTANephrology Dialysis Transplantation, 2020